Johnson Matthey Cormetech acquisition explained: a bigger bet on clean air and US power generation
Johnson Matthey has agreed to buy Cormetech, a US manufacturer of Selective Catalytic Reduction catalysts, or SCR catalysts. In simple terms, these are products used to cut harmful nitrogen oxides emissions from power generation and industrial plants.
This is not a small tuck-in deal. Johnson Matthey, or JM, is paying an enterprise value of $360 million in cash on completion, with a possible further earn-out of up to $100 million in 2028 and 2029 if Cormetech hits certain financial targets.
For retail investors, the headline is straightforward: JM is using this acquisition to bulk up its Clean Air Solutions business and push harder into a US market that it thinks has strong long-term growth, helped by rising electricity demand from data centres.
Johnson Matthey acquisition of Cormetech: the key numbers investors should know
| Metric | Figure | Why it matters |
|---|---|---|
| Purchase price | $360 million | Cash paid on completion |
| Possible earn-out | Up to $100 million | Only payable if performance targets are met |
| Acquisition multiple | 10.3x expected 2026 EBITDA | Not cheap, but not outrageous for a growth asset |
| Multiple including synergies | c.6.5x EBITDA | Looks much more attractive if JM delivers the plan |
| Cormetech expected 2026 sales | c.$180 million | Shows the scale JM is buying |
| Cormetech expected 2026 EBITDA | c.$35 million | Core profit measure before interest, tax, depreciation and amortisation |
| Run-rate synergies | At least $20 million | Big uplift if achieved by 2030 |
| One-off synergy costs | Approximately $6 million | Relatively modest integration cost |
| Secured orderbook | c.$300 million | Supports 2026 and 2027 revenues |
| Project pipeline | c.$1 billion | Suggests plenty of medium-term opportunity |
Why Johnson Matthey wants Cormetech and why the US power market matters
The strategic logic is pretty clear. JM already has a Clean Air Solutions business selling emissions control products into stationary engines in marine, industrial and utilities markets. Cormetech adds a leading position in SCR catalysts for natural gas turbines and coal-fired power plants, especially in the US.
That matters because JM sees structural growth here, not just a temporary bump. The company says the rapid build-out of data centres is increasing demand for power generation, while tighter US nitrogen oxides rules are pushing operators towards cleaner emissions control technology.
Put another way, more electricity demand plus stricter environmental standards can be a very good combination for a catalyst supplier. JM is trying to place itself in the middle of that trend.
Cormetech strengthens Johnson Matthey Clean Air Solutions with scale, recurring revenue and IP
There are a few attractive features in Cormetech’s business model. First, it has over 400 customers, and 90% of them have used its products for more than a decade. That suggests sticky relationships and a high barrier to switching.
Second, it has the largest global installed SCR catalyst base, operating in over 2,500 systems with more than 300GW of generation capacity worldwide. Installed bases matter because they tend to create recurring replacement sales, and JM says those sales are protected by Cormetech’s intellectual property.
Third, Cormetech has been growing quickly. It delivered 2025 sales of $129 million and EBITDA of $16 million, and expects that to rise to around $180 million of sales and around $35 million of EBITDA in 2026. That is a sharp step up.
JM’s existing Clean Air Solutions business generated £67 million of sales and £10 million of underlying operating profit in 2025/26. Combined, the two businesses are expected to produce sales of more than £200 million and an operating margin of at least mid-teens in 2026/27. That starts to look like a more meaningful business unit inside the group.
Is the Johnson Matthey Cormetech deal good value? The case for and against
At first glance, paying 10.3x expected 2026 EBITDA is not exactly bargain-bin stuff. Investors are being asked to trust the growth story and the synergy case.
That said, the picture improves if JM delivers what it says. Including the at least $20 million of run-rate synergies, the effective multiple drops to around 6.5x EBITDA. That looks far more appealing.
The other reassuring point is that this is not a pure hope trade. Cormetech has a secured orderbook of around $300 million for delivery in 2026 and 2027, plus a project pipeline of around $1 billion, mainly tied to US data centre-related projects. That gives the growth argument some substance.
My view is that this looks strategically smart, but execution will decide whether it becomes financially impressive. Revenue synergies make up around 70% of the total synergy target, and those are usually harder to bank than straightforward cost cuts.
What this means for Johnson Matthey shareholders, dividends, buybacks and debt
One concern with acquisitions is whether they derail shareholder returns. JM is trying hard to say they will not.
The company says it remains on track to return £1 billion of net proceeds to shareholders after the sale of its Catalyst Technologies business to Honeywell International, with completion of that sale expected by the end of August 2026. It also reiterated guidance for annualised sustainable free cash flow of at least £250 million by 2027/28, supporting shareholder returns of at least £200 million per annum from 2026/27 onwards through ordinary dividends and share buybacks.
The acquisition will be funded from existing debt facilities. After the Cormetech acquisition, the Catalyst Technologies sale and the £1 billion return to shareholders, JM expects pro forma leverage of about 1.8 times net debt to EBITDA as at 31 March 2027.
That is above its 1.0 to 1.5 times target range, but not alarmingly so. Management expects strong cash generation to bring leverage back inside the target range by 31 March 2029. The interest cost of that debt is not disclosed in this announcement.
Risks in the Cormetech deal: what could go wrong from here?
- Regulatory approval risk – the deal is still subject to customary approvals and is expected to complete at the end of June or in July 2026.
- Integration risk – JM says it has a detailed plan, but combining businesses always carries some disruption risk.
- Synergy risk – a large part of the synergy case depends on cross-selling and winning new customers, which is less certain than cutting procurement costs.
- End-market concentration – the US power generation opportunity looks strong, but it does increase JM’s reliance on that market continuing to expand as expected.
My take on the Johnson Matthey Cormetech acquisition for retail investors
I think this is a positive RNS overall. It shows JM continuing to reshape itself around areas where it believes it has stronger competitive advantages, and this deal looks much more focused than sprawling.
The best part of the announcement is that it joins strategy and numbers up reasonably well. JM is not just saying the market is attractive – it is buying a market leader with visible customer relationships, recurring replacement demand and a sizeable orderbook.
The weak spot is the reliance on future delivery. The headline valuation only looks compelling once synergies are included, and some of those synergies are commercial rather than purely operational. Investors should keep a close eye on whether the enlarged Clean Air Solutions business actually hits that promised scale and margin profile.
Still, if you want the short version, here it is: Johnson Matthey is buying growth, scale and stronger US exposure in emissions control, while insisting it can still fund shareholder returns. If management executes properly, this could be one of the more convincing pieces of its strategic reset.
